Nobel laureate Phillip A. Sharp, who has chaired the Stand Up To Cancer scientific advisory committee since SU2C launched in 2008 is transitioning to emeritus status at the organization.
Stand Up To Cancer and Johnson & Johnson announced a collaboration aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.
